Nanjing Well Pharmaceutical Co Ltd (603351) - Net Assets
Based on the latest financial reports, Nanjing Well Pharmaceutical Co Ltd (603351) has net assets worth CN¥1.77 Billion CNY (≈ $258.44 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.59 Billion ≈ $378.33 Million USD) and total liabilities (CN¥819.31 Million ≈ $119.89 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 603351 financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.77 Billion |
| % of Total Assets | 68.31% |
| Annual Growth Rate | 21.66% |
| 5-Year Change | 31.43% |
| 10-Year Change | 480.05% |
| Growth Volatility | 28.99 |
Nanjing Well Pharmaceutical Co Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Nanjing Well Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Nanjing Well Pharmaceutical Co Ltd for the complete picture of this company's asset base.
Annual Net Assets for Nanjing Well Pharmaceutical Co Ltd (2014–2024)
The table below shows the annual net assets of Nanjing Well Pharmaceutical Co Ltd from 2014 to 2024. For live valuation and market cap data, see market cap of Nanjing Well Pharmaceutical Co Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.71 Billion ≈ $249.96 Million |
+7.25% |
| 2023-12-31 | CN¥1.59 Billion ≈ $233.06 Million |
+7.44% |
| 2022-12-31 | CN¥1.48 Billion ≈ $216.92 Million |
+7.00% |
| 2021-12-31 | CN¥1.39 Billion ≈ $202.73 Million |
+6.60% |
| 2020-12-31 | CN¥1.30 Billion ≈ $190.18 Million |
+4.71% |
| 2019-12-31 | CN¥1.24 Billion ≈ $181.63 Million |
+101.95% |
| 2018-12-31 | CN¥614.61 Million ≈ $89.94 Million |
+15.36% |
| 2017-12-31 | CN¥532.80 Million ≈ $77.96 Million |
+20.00% |
| 2016-12-31 | CN¥443.99 Million ≈ $64.97 Million |
+50.76% |
| 2015-12-31 | CN¥294.49 Million ≈ $43.09 Million |
+22.52% |
| 2014-12-31 | CN¥240.35 Million ≈ $35.17 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nanjing Well Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 180.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥555.70 Million | 32.65% |
| Common Stock | CN¥135.44 Million | 7.96% |
| Other Comprehensive Income | CN¥67.88 Million | 3.99% |
| Other Components | CN¥942.90 Million | 55.40% |
| Total Equity | CN¥1.70 Billion | 100.00% |
Nanjing Well Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Nanjing Well Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Viromed Medical AG
DU:Q11
|
$537.97 Million |
|
Continental Holdings Corp
TW:3703
|
$538.17 Million |
|
Sichuan Dawn Precision Technology Co Ltd
SHE:300780
|
$538.28 Million |
|
SHANDONG BOAN BIOTECH.H 1
F:UJ9
|
$538.40 Million |
|
IS Dongseo
KO:010780
|
$537.84 Million |
|
Neosem Inc
KQ:253590
|
$537.71 Million |
|
Hunan Chen Dian International Development Co Ltd
SHG:600969
|
$537.71 Million |
|
Nanjing CEC Environmental Protect
SHE:300172
|
$537.70 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nanjing Well Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,584,423,033 to 1,701,923,864, a change of 117,500,831 (7.4%).
- Net income of 146,421,823 contributed positively to equity growth.
- Dividend payments of 55,466,885 reduced retained earnings.
- Other comprehensive income increased equity by 65,095,188.
- Other factors decreased equity by 38,549,295.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥146.42 Million | +8.6% |
| Dividends Paid | CN¥55.47 Million | -3.26% |
| Other Comprehensive Income | CN¥65.10 Million | +3.82% |
| Other Changes | CN¥-38.55 Million | -2.27% |
| Total Change | CN¥- | 7.42% |
Book Value vs Market Value Analysis
This analysis compares Nanjing Well Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.16x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.45x to 2.16x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | CN¥4.21 | CN¥27.14 | x |
| 2015-12-31 | CN¥5.17 | CN¥27.14 | x |
| 2016-12-31 | CN¥4.52 | CN¥27.14 | x |
| 2017-12-31 | CN¥5.44 | CN¥27.14 | x |
| 2018-12-31 | CN¥6.28 | CN¥27.14 | x |
| 2019-12-31 | CN¥9.50 | CN¥27.14 | x |
| 2020-12-31 | CN¥9.95 | CN¥27.14 | x |
| 2021-12-31 | CN¥10.58 | CN¥27.14 | x |
| 2022-12-31 | CN¥11.16 | CN¥27.14 | x |
| 2023-12-31 | CN¥11.72 | CN¥27.14 | x |
| 2024-12-31 | CN¥12.55 | CN¥27.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nanjing Well Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.60%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.29%
- • Asset Turnover: 0.54x
- • Equity Multiplier: 1.40x
- Recent ROE (8.60%) is below the historical average (12.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 18.68% | 8.50% | 1.26x | 1.75x | CN¥20.83 Million |
| 2015 | 20.63% | 12.17% | 1.02x | 1.66x | CN¥31.26 Million |
| 2016 | 16.61% | 13.19% | 0.93x | 1.35x | CN¥29.31 Million |
| 2017 | 20.16% | 15.48% | 0.96x | 1.36x | CN¥54.15 Million |
| 2018 | 18.19% | 13.95% | 0.99x | 1.31x | CN¥50.35 Million |
| 2019 | 10.32% | 14.55% | 0.60x | 1.17x | CN¥3.99 Million |
| 2020 | 7.73% | 13.65% | 0.45x | 1.26x | CN¥-29.52 Million |
| 2021 | 7.33% | 9.73% | 0.57x | 1.33x | CN¥-36.90 Million |
| 2022 | 6.42% | 8.55% | 0.52x | 1.44x | CN¥-53.00 Million |
| 2023 | 7.08% | 9.71% | 0.51x | 1.44x | CN¥-46.24 Million |
| 2024 | 8.60% | 11.29% | 0.54x | 1.40x | CN¥-23.77 Million |
Industry Comparison
This section compares Nanjing Well Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nanjing Well Pharmaceutical Co Ltd (603351) | CN¥1.77 Billion | 18.68% | 0.46x | $537.89 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Nanjing Well Pharmaceutical Co Ltd
Nanjing Well Pharmaceutical Group Co.,Ltd. focuses on the research and development, production, and sale of pharmaceutical excipients and synthetic lubricating base oils to the pharmaceutical companies in China. It is involved in the bio-based material manufacturing, sales, and technology development; technical development and consulting; bio-based material technology research and development; bi… Read more